Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series.
Despite well-documented improvement in attention deficit hyperactivity disorder (ADHD) in youths with the available single and combined pharmacologic agents, a number of youths remain with residual symptomatology causing impairment in multiple domains. Recent work has suggested a potential cognitive-enhancing role of cholinergic agents in ADHD. We describe five cases of ADHD youths aged 8-17 years being treated for ADHD with the acetylcholinesterase inhibitor donepezil (Aricept), all of whom demonstrated improvement.
Wilens
T E
TE
Pediatric Psychopharmacology Unit, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA. wilens@helix.mgh.harvard.edu
Biederman
J
J
Wong
J
J
Spencer
T J
TJ
Prince
J B
JB
D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002648:Child; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D000077265:Donepezil; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D010880:Piperidines / Q000627:therapeutic use*
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil